Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 21 min ago
PreprintAll rights reservedmedRxiv

A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial

  • N. B. Pandey1
  • A. C. Mirando
  • D. R. P. Almeida
  • S. Dang
  • D. R. Lally
  • W. Z. Bridges
  • P. A. Campochiaro
  • A. S. Popel
  • J. J. Green
  1. 1Johns Hopkins University School of Medicine
Read full textPDFDOICite

Related

  1. Association Between the Social Deprivation Index and Neovascular Age-Related Macular Degeneration Outcomes
    Rohini Dasan, Mike Y. Chen, Jeanette Du +4
    Journal of Vitreoretinal DiseasesPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC
  2. Real-world anatomical and functional outcomes following Faricimab therapy in neovascular age-related macular degeneration: a one-year observational study
    Settimio Rossi, Carlo Gesualdo, Maria Consiglia Trotta +6
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration : A Post Hoc Analysis of the TENAYA and LUCERNE Trials
    Colin S. Tan, Benjamin Bakall, Adrian Hock Chuan Koh +8
    JAMA ophthalmologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Changes in expression of DNA-methyltransferase in neovascular age-related macular degeneration: Anti-VEGF response or disease severity?
    Pedro Camacho, Edna Ribeiro, Bruno Pereira +9
    American Journal of Ophthalmology Case ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMCEurope PMC
  5. Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report
    Ching-Hua Hsu, Acer I-Hung Chen, Chien-Hsiung Lai +1
    BMC OphthalmologyPeer-reviewedCC BYFull textGeneral medicineDOAJ

Cite

BibTeXRIS
BibTeX
@misc{pandey2026single,
  title = {{A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial}},
  author = {N. B. Pandey and A. C. Mirando and D. R. P. Almeida and S. Dang and D. R. Lally and W. Z. Bridges and P. A. Campochiaro and A. S. Popel and J. J. Green},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.19.26363031},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.19.26363031v1},
}
RIS
TY  - UNPB
TI  - A Single Suprachoroidal Injection of AXT107 (Gersizangitide), a Multimodal, Long-Acting Integrin-Disrupting Peptide, in Patients with Neovascular Age-Related Macular Degeneration: Results of the Phase 1/2a DISCOVER Trial
AU  - N. B. Pandey
AU  - A. C. Mirando
AU  - D. R. P. Almeida
AU  - S. Dang
AU  - D. R. Lally
AU  - W. Z. Bridges
AU  - P. A. Campochiaro
AU  - A. S. Popel
AU  - J. J. Green
PY  - 2026
DA  - 2026/09/19
PB  - medRxiv
DO  - 10.64898/2026.09.19.26363031
UR  - https://www.medrxiv.org/content/10.64898/2026.09.19.26363031v1
ER  -